financetom
Business
financetom
/
Business
/
Oculis Sees Favorable Topline Results in Study of Potential Dye-Eye Disease Treatment
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Oculis Sees Favorable Topline Results in Study of Potential Dye-Eye Disease Treatment
Jun 10, 2024 4:01 AM

06:44 AM EDT, 06/10/2024 (MT Newswires) -- Oculis Holding (OCS) said Monday it had detected favorable topline results from a phase 2b trial of licaminlimab for the treatment of patients with dry-eye disease.

The 122-patient study showed treatment effects "favoring" licaminlimab in multiple sign endpoints accepted by the US Food and Drug Administration.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved